相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel therapeutic agents for B-cell lymphoma: developing rational combinations
Craig B. Reeder et al.
BLOOD (2011)
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
Mohamad Hussein et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
Richard R. Furman et al.
LEUKEMIA & LYMPHOMA (2010)
Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies
Robert J. Kreitman
BIODRUGS (2009)
Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease
S. Shteingart et al.
GUT (2009)
IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitis
Michal Irony-Tur-Sinai et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2009)
Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
Robert J. Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
Ranjana Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Anti-CD40 Monoclonal Antibody Synergizes with CTLA4-Ig in Promoting Long-Term Graft Survival in Murine Models of Transplantation
Christopher R. Gilson et al.
JOURNAL OF IMMUNOLOGY (2009)
Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation
Xian-Liang Li et al.
TRANSPLANTATION (2008)
CD40/CD40L system and vascular disease
F. Santilli et al.
INTERNAL AND EMERGENCY MEDICINE (2007)
Novel fully human Anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys
Atsushi Imai et al.
TRANSPLANTATION (2007)
Cholesterol-dependent and - Independent CD40 internalization and signaling activation in cardiovascular endothelial cells
Jianjun Chen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Alemtuzumab in CLL and other lymphoid neoplasms
Farhad Ravandi et al.
CANCER INVESTIGATION (2006)
Immunotoxins for targeted cancer therapy
Robert J. Kreitman
AAPS JOURNAL (2006)
Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury
MJ Segel et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2005)
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-Cell malignancies
RJ Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The anthracycline antibiotics: antitumor drugs that alter chromatin structure
A Rabbani et al.
BIOESSAYS (2005)
Mechanism of action and resistance to monoclonal antibody therapy
N Villamor et al.
SEMINARS IN ONCOLOGY (2003)
Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor
R Aqeilan et al.
BIOCHEMICAL JOURNAL (2003)
The role of CD154 in organ transplant rejection and acceptance
AD Kirk et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2001)
GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins
Y Azar et al.
APOPTOSIS (2000)
High bax expression is a good prognostic indicator in acute myeloid leukaemia
YL Ong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
CD154 (CD40 ligand)
U Schönbeck et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2000)
Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling
BS Hostager et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
